There is no doubt that the apparent success of the Pfizer vaccine and the EUA for the minimally effective in mild Covid Lilly mAb takes the wind out of Cytodyn’s sails, thus this morning’s blood bath.

Until CD12 results, I expected low 2s, but here we are.

Nonetheless, there remains no definitive treatment for severe Covid, excepting dexamethasone with moderate effect and a number of limitations in its use.

However, the mild Covid is not the big game and the US is not the world. Thus we don’t see other countries rushing to remdesivir or likely to bamlanivimab. Please remember that bamlanivimab trials in severe Covid were halted just two weeks ago for lack of efficacy in hospitalized patients, yet the FDA strikes again.

With an average price well over 3, I am less sanguine about my situation than those under $1. Nonetheless, either leronlimab is proven effective as expected in January or it is not.

I take the long view and accept the process.